Liverpool has extensive expertise in several key areas involved in the development, clinical assessment and pharmacological evaluation of new cancer treatments. The Liverpool ECMC will facilitate the full integration and optimal exploitation of these resources for phas

• Pharmacology, Toxicology and Drug Development.
• Basic cancer cell biology and imaging.
• Pancreas cancer.
• Head and Neck cancer.
• Gynaecological cancers.
• Lung cancer.
• Breast, prostate, renal, colorectal, oesophago-gastric, melanoma, brain.
• Chronic lymphocytic leukaemia, chronic myeloid leukaemia.
• Lymphoma.
• Vast Tissue collection.